ZA200904230B - Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline - Google Patents

Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline

Info

Publication number
ZA200904230B
ZA200904230B ZA200904230A ZA200904230A ZA200904230B ZA 200904230 B ZA200904230 B ZA 200904230B ZA 200904230 A ZA200904230 A ZA 200904230A ZA 200904230 A ZA200904230 A ZA 200904230A ZA 200904230 B ZA200904230 B ZA 200904230B
Authority
ZA
South Africa
Prior art keywords
methyl
pyrazol
pyridin
quinoline
phenoxy
Prior art date
Application number
ZA200904230A
Other languages
English (en)
Inventor
Patrick Robert Vorhoest
Caroline Proulx
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39321475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904230(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200904230B publication Critical patent/ZA200904230B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200904230A 2006-12-21 2009-06-17 Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline ZA200904230B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87126006P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
ZA200904230B true ZA200904230B (en) 2010-04-28

Family

ID=39321475

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904230A ZA200904230B (en) 2006-12-21 2009-06-17 Succinate salt of 2-((4-(1-methyl-4-(pyridin-44-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline

Country Status (24)

Country Link
US (1) US8283471B2 (enExample)
EP (1) EP2125786B1 (enExample)
JP (1) JP5254602B2 (enExample)
KR (2) KR20090092338A (enExample)
CN (1) CN101611029B (enExample)
AR (1) AR064417A1 (enExample)
AT (1) ATE502028T1 (enExample)
AU (1) AU2007343135B2 (enExample)
BR (1) BRPI0720936A2 (enExample)
CA (1) CA2673435C (enExample)
CY (1) CY1111919T1 (enExample)
DE (1) DE602007013294D1 (enExample)
DK (1) DK2125786T3 (enExample)
ES (1) ES2360014T3 (enExample)
IL (1) IL199389A (enExample)
MX (1) MX2009006528A (enExample)
NZ (1) NZ577716A (enExample)
PL (1) PL2125786T3 (enExample)
PT (1) PT2125786E (enExample)
RU (1) RU2430918C2 (enExample)
SI (1) SI2125786T1 (enExample)
TW (1) TWI359660B (enExample)
WO (1) WO2008084299A1 (enExample)
ZA (1) ZA200904230B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120214842A1 (en) * 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR102233916B1 (ko) * 2019-05-28 2021-03-30 주식회사 엘지생활건강 Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006072828A2 (en) * 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2006078825A2 (en) 2005-01-21 2006-07-27 Cabot Corporation Processes for forming nanoparticles
AU2006329849A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound

Also Published As

Publication number Publication date
CA2673435C (en) 2012-10-09
KR20090092338A (ko) 2009-08-31
BRPI0720936A2 (pt) 2014-03-11
AR064417A1 (es) 2009-04-01
ATE502028T1 (de) 2011-04-15
JP5254602B2 (ja) 2013-08-07
AU2007343135A1 (en) 2008-07-17
IL199389A (en) 2014-01-30
CN101611029A (zh) 2009-12-23
HK1134670A1 (en) 2010-05-07
EP2125786B1 (en) 2011-03-16
PL2125786T3 (pl) 2011-07-29
EP2125786A1 (en) 2009-12-02
SI2125786T1 (sl) 2011-05-31
TWI359660B (en) 2012-03-11
MX2009006528A (es) 2009-06-26
WO2008084299A1 (en) 2008-07-17
NZ577716A (en) 2012-10-26
PT2125786E (pt) 2011-04-21
US20100063089A1 (en) 2010-03-11
CY1111919T1 (el) 2015-11-04
ES2360014T3 (es) 2011-05-31
RU2009123347A (ru) 2011-01-27
TW200833337A (en) 2008-08-16
AU2007343135B2 (en) 2013-03-21
JP2008208114A (ja) 2008-09-11
RU2430918C2 (ru) 2011-10-10
CA2673435A1 (en) 2008-07-17
DK2125786T3 (da) 2011-05-09
DE602007013294D1 (de) 2011-04-28
KR20120043775A (ko) 2012-05-04
CN101611029B (zh) 2014-09-10
US8283471B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
SI2625175T1 (sl) Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr
ZA200709715B (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
HRP20170241T1 (hr) Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
EP2038272B8 (en) Pyridinonyl pdk1 inhibitors
IL196876A0 (en) 2-(heterocyclylbenzyl)pyridazinone derivatives
SI2503993T1 (sl) Hidrokloridna sol 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oksi) etil)morfolina
TWI371275B (en) Heterocyclic amide compounds as protein kinase inhibitors
IL197420A0 (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-
ZA200802488B (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
ZA201001513B (en) 5-(4-(Haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
IL191584A0 (en) Homo and heterocyclic compounds suitable as cetp inhibitors
IL199389A (en) 2-Oxide salt ((4 - (1-methyl-4-pyridine-4-yl) -h1-pyrrolysis-3-yl) phenoxy) quinoline
IL194549A0 (en) 2-(pyridin-2-yl)-pyrimidines for use as fungicides
PL2137160T3 (pl) 4-(4-trifluorometylo-3-tiobenzoilo)pirazole i ich zastosowanie jako herbicydów
IL220851A (en) Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
ZA201003031B (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
SI2220027T1 (sl) Polimorfna oblika N-(4-(trifluorometil)benzil)-4-metoksibutiramid
AU2006317419B2 (en) 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
HK1146903A (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
HK1141794A (en) Heterocyclic amide compounds as protein kinase inhibitors
HK1138845A (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors